/
CNTX
$0.58-$0.00 (-0.50%)live
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$53.3M
92M shares
52-week range
$0.55 – $3.62
1% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Price (6 mo)
Loading chart…
Change$-4.52
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross profit | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross margin | — | — | — | — | — | — | — |
| R&D | $2.4M | $1.6M | $3.8M | $7.1M | $17.8M | $22.7M | $31.9M |
| Operating income | −$5.4M | −$2.6M | −$10.5M | −$15.4M | −$25.1M | −$29.9M | −$39.7M |
| EBITDA | −$5.4M | −$2.6M | −$7.4M | −$14.9M | −$24.0M | −$26.7M | −$36.1M |
| Net income | −$6.4M | $6.6M | −$10.5M | −$14.8M | −$24.0M | −$26.7M | −$36.1M |
| Net margin | — | — | — | — | — | — | — |
| EPS (diluted) | -0.68 | -0.80 | -3.69 | -0.93 | -1.50 | -0.46 | -0.38 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $2M | $-0.39 | $-0.48–$-0.26 | 7 |
| 2027 | $0 | $-0.43 | $-0.54–$-0.27 | 6 |
| 2028 | $2M | $-0.53 | $-0.78–$-0.27 | 7 |
| 2029 | $11M | $-0.46 | $-0.46–$-0.46 | 2 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$0.67
Price
$0.58
Implied upside
+16%
Peer comparison
Context Therapeutics Inc. Common Stock
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.
www.contexttherapeutics.com- Employees
- 15
- IPO / List date
- Oct 20, 2021
- HQ
- PHILADELPHIA, PA
Held by traders on TradeandTell
No one on the platform currently holds CNTX.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 182,999 | $479.5K |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded CNTX yet.
